Porownywarka

Pinealon vs Epithalon side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

PinealonEpithalon

Udostępnij porównanie peptydów

Wlasciwosc	Pinealon	Epithalon
Kategoria	Bioregulatory	Bioregulatory
Znany tez jako	EDR, Glu-Asp-Arg	Epitalon, Epithalone, AGAG
Zatwierdzony przez FDA	Nie	Nie
Status kliniczny	Available in Russia - Not FDA approved Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Investigational; primarily Russian research. Source notes current FDA Category 2 status pending formal reclassification activity in 2026. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Brain health, sleep, cognitive aging, neuroprotection	Longevity, telomere support, anti-aging, sleep
Jak dziala	Pinealon/EDR is proposed to act as a short peptide bioregulator with epigenetic effects on gene expression and protein synthesis. The supplied source reports that, in neuronal cell systems and related models, Pinealon reduced oxidative-stress-associated reactive oxygen species, lowered necrotic and apoptotic cell death, and affected ERK 1/2 signaling and cell-cycle timing. These mechanisms are not confirmed in human brain studies in the provided evidence.	Epithalon is proposed to act through telomerase-related biology, with cell-culture reports describing telomerase activity and telomere elongation in human fibroblasts. The source also notes possible effects on melatonin, antioxidant defenses, and gene expression in pineal-hypothalamic pathways. Translation from these observations to meaningful human anti-aging outcomes remains unproven in the supplied evidence.
Typowe dawkowanie	10-20 mg daily · Once daily, typically evening	5-10 mg daily for 10-20 days · Once daily in cycles · 10-20 days
Dawkowanie z badań	10-20 mg daily · 10-30 day courses · Oral or sublingual	5-10 mg daily for 10-20 days · 10-20 day cycles · Subcutaneous or intramuscular injection
Typowy czas trwania	10-30 day courses	10-20 day cycles
Podanie	Oral or sublingual	Subcutaneous or intramuscular injection
Timing	Evening or before bed With or without food	Before bed With or without food
Poziom dowodów	Przedkliniczne	Badania kliniczne
Mozliwe skutki uboczne	Generally well tolerated (Source-reported general tolerability statement; no human safety dataset was supplied.) Headache (Listed by the source as a reported side effect.) Nausea (Listed by the source as a reported side effect.) +4 więcej Dizziness (Listed by the source as a reported side effect.) Vivid dreams (Listed by the source as a reported side effect.) Injection site reactions (Listed by the source, although the main administration evidence says oral or sublingual.) Caution with seizure disorders (Source flags this caution, but the supplied evidence does not quantify risk.)	Generally well-tolerated (Reported in the source, but tolerability evidence is limited by the available research base.) Injection site reactions (Reported as a possible effect with injectable administration.) Mild headache (Source describes this as transient.) +3 więcej Sleep disturbances (Reported as a possible effect; frequency is not established.) Risk of immunogenicity (Listed as a potential risk rather than a quantified event rate.) Long-term safety not established (The source explicitly notes uncertainty about long-term safety.)
Podsumowanie researchu	The supplied source places Pinealon in a preclinical evidence base centered on Russian peptide-bioregulator research. Reported models include cultured cerebellar granule neurons, neutrophils, and PC12 cells, where Pinealon was associated with lower oxidative-stress ROS accumulation, reduced cell death, increased viability, and proliferative activity. Related EDR work is described in Alzheimer's-type in vitro and in vivo models, and the source notes overlap with Cortexin-related activity. The source also states that randomized human trials, human pharmacokinetic data, and human safety data were not available in the cited evidence.	The supplied research narrative gives greatest weight to laboratory and animal data. It cites a 2003 report by Khavinson and colleagues on telomerase activity and telomere changes in cultured human fibroblasts, plus a 2025 review discussing geroprotective and neuroendocrine research. Animal studies are described as reporting lifespan and tumor-incidence findings. Human evidence is characterized as limited, often small or open-label, and not independently replicated at the scale needed to prove lifespan extension or reliable telomere-length effects in people.
Referencje	PubMed PMC +2 więcej PMC PubMed	PubMed PubMed +2 więcej WikipediaEpitalon Springer
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Pinealon

Epithalon

Kategoria

Bioregulatory

Znany tez jako

EDR, Glu-Asp-Arg

Epitalon, Epithalone, AGAG

Zatwierdzony przez FDA

Nie

Status kliniczny

Available in Russia - Not FDA approved

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Investigational; primarily Russian research. Source notes current FDA Category 2 status pending formal reclassification activity in 2026.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Brain health, sleep, cognitive aging, neuroprotection

Longevity, telomere support, anti-aging, sleep

Jak dziala

Pinealon/EDR is proposed to act as a short peptide bioregulator with epigenetic effects on gene expression and protein synthesis. The supplied source reports that, in neuronal cell systems and related models, Pinealon reduced oxidative-stress-associated reactive oxygen species, lowered necrotic and apoptotic cell death, and affected ERK 1/2 signaling and cell-cycle timing. These mechanisms are not confirmed in human brain studies in the provided evidence.

Epithalon is proposed to act through telomerase-related biology, with cell-culture reports describing telomerase activity and telomere elongation in human fibroblasts. The source also notes possible effects on melatonin, antioxidant defenses, and gene expression in pineal-hypothalamic pathways. Translation from these observations to meaningful human anti-aging outcomes remains unproven in the supplied evidence.

Typowe dawkowanie

10-20 mg daily · Once daily, typically evening

5-10 mg daily for 10-20 days · Once daily in cycles · 10-20 days

Dawkowanie z badań

10-20 mg daily · 10-30 day courses · Oral or sublingual

5-10 mg daily for 10-20 days · 10-20 day cycles · Subcutaneous or intramuscular injection

Typowy czas trwania

10-30 day courses

10-20 day cycles

Podanie

Oral or sublingual

Subcutaneous or intramuscular injection

Timing

Evening or before bed

With or without food

Before bed

With or without food

Poziom dowodów

Przedkliniczne

Badania kliniczne

Mozliwe skutki uboczne

Generally well tolerated (Source-reported general tolerability statement; no human safety dataset was supplied.)
Headache (Listed by the source as a reported side effect.)
Nausea (Listed by the source as a reported side effect.)

+4 więcej

Dizziness (Listed by the source as a reported side effect.)
Vivid dreams (Listed by the source as a reported side effect.)
Injection site reactions (Listed by the source, although the main administration evidence says oral or sublingual.)
Caution with seizure disorders (Source flags this caution, but the supplied evidence does not quantify risk.)

Generally well-tolerated (Reported in the source, but tolerability evidence is limited by the available research base.)
Injection site reactions (Reported as a possible effect with injectable administration.)
Mild headache (Source describes this as transient.)

+3 więcej

Sleep disturbances (Reported as a possible effect; frequency is not established.)
Risk of immunogenicity (Listed as a potential risk rather than a quantified event rate.)
Long-term safety not established (The source explicitly notes uncertainty about long-term safety.)

Podsumowanie researchu

The supplied source places Pinealon in a preclinical evidence base centered on Russian peptide-bioregulator research. Reported models include cultured cerebellar granule neurons, neutrophils, and PC12 cells, where Pinealon was associated with lower oxidative-stress ROS accumulation, reduced cell death, increased viability, and proliferative activity. Related EDR work is described in Alzheimer's-type in vitro and in vivo models, and the source notes overlap with Cortexin-related activity. The source also states that randomized human trials, human pharmacokinetic data, and human safety data were not available in the cited evidence.

The supplied research narrative gives greatest weight to laboratory and animal data. It cites a 2003 report by Khavinson and colleagues on telomerase activity and telomere changes in cultured human fibroblasts, plus a 2025 review discussing geroprotective and neuroendocrine research. Animal studies are described as reporting lifespan and tumor-incidence findings. Human evidence is characterized as limited, often small or open-label, and not independently replicated at the scale needed to prove lifespan extension or reliable telomere-length effects in people.

Referencje

PubMed PMC

+2 więcej

PMC PubMed

PubMed PubMed

+2 więcej

WikipediaEpitalon Springer

Pełny profil

Zobacz szczegóły